Actively Recruiting
Safety and Feasibility Study of the SiroMax Sirolimus-Coated Balloon Catheter for Treating Coronary Artery Disease Including In-Stent Restenosis and Small Vessel Lesions
Led by Tonic Medical, Inc. · Updated on 2026-09-14
60
Participants Needed
2
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the safety and effectiveness of the SiroMax17 drug-coated balloon catheter to treat narrowed coronary arteries in adults with coronary artery disease, including those with in-stent restenosis ISR or new lesions in small vessels. This prospective, open-label trial will enroll up to 60 subjects across multiple sites outside the United States, dividing them into ISR and de novo small vessel DNSV groups. A subgroup of ISR participants will join a pharmacokinetic study to understand the drugs elimination. Participants will receive treatment with the SiroMax sirolimus-coated balloon catheter targeting a single lesion per procedure. The ISR arm treats lesions within previously stented segments while the DNSV arm treats lesions in small vessels. All subjects undergo angiographic assessment during the procedure, and any non-target lesions may be treated with standard devices during the index procedure. The trial includes follow-up visits up to 5 years post-treatment, with additional visits for the pharmacokinetic subgroup. During the study, participants will be evaluated at hospital discharge, 30 days, 3 months, 6 months, 12 months, and annually through 5 years. Assessments include monitoring for major adverse cardiac events such as cardiac death, heart attack, and stroke, as well as target lesion failure. The pharmacokinetic subgroup will have an extra visit at 7 days. Researchers will collect data on safety and efficacy through clinical evaluations and angiographic imaging to understand device performance and patient outcomes over time.
CONDITIONS
Brief Title
First-in-Human Study Using the SiroMax™ Sirolimus-Coated Balloon Catheter as a Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter to Treat Subjects Who Have Coronary Artery Disease (CAD) Involving In-Stent Restenosis (ISR) or an Unstented Lesion in a Small Coronary Vessel (DNSV).
Research Team
C
Chief Operating Officer
J
Jill Moland
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here